BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair
Anastasia Geladaris(Fraunhofer Institute for Translational Medicine and Pharmacology), Martin S. Weber(Fraunhofer Institute for Translational Medicine and Pharmacology)
Cited by 39
Related Papers
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
|Nature Medicine|2007|448
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
|New England Journal of Medicine|2019|320
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials
|Therapeutic Advances in Neurological Disorders|2024|23